2025-06-09-花旗集团-LENZ治疗公司（LENZ）_LENZ_Therapeutics_Inc（LENZ.O）2025年第一季度模型更新_13页_494kb

LENZ Therapeutics Inc (LENZ.O) 1Q25 Model Update Summary

Core Content Overview

LENZ Therapeutics Inc (LENZ.O) is a late-stage clinical biotechnology company focused on developing ophthalmic therapies to improve vision, particularly targeting presbyopia. The company's lead product candidate, LNZ100 (aceclidine), is a once-daily eye drop designed to enhance near vision and serves as an alternative to reading glasses. Citi Research has updated its financial model for 1Q25 and revised its target price for LENZ.

Key Financial Model Adjustments

• Target Price: Revised from $47 to $45, reflecting updated assumptions about share count and earnings.
• Expected Share Price Return: 40.8%
• Market Cap: $900M
• EPS Projections (2025E):
  • Q1: -$0.53A
  • Q2: -$0.77E
  • Q3: -$0.87E
  • Q4: -$0.78E
  • FY2025: -$3.01E
• Core EPS (2025E): -$3.01
• Share Count: Weighted average shares increased from 21.3M in 2024 to 27.5M in 2025 and beyond.

Revenue and Profit Projections

• Sales Revenue (2025E): $7.1M (up from $0 in 2024)
• Gross Profit (2025E): $6.9M (97.3% gross margin)
• EBIT (Adj) (2025E): -$85.8M (EBIT margin: -175.3%)
• Pre-tax Profit (2025E): -$82.8M
• Net Profit (2025E): -$82.8M
• Net Margin (2025E): -173.3%

Valuation Ratios

• PE (2025E): -10.6
• PB (2025E): 7.0
• EV/EBITDA (2025E): -8.5
• FCF Yield (2025E): -9.1%
• ROE (2025E): -50.1%

Catalyst Watch

• Direction: Upside
• Duration: Within 90 days
• Expected Event Date: August 8, 2025 (PDUFA date)
• Catalyst: FDA approval for LNZ100
• Analyst Confidence: High
• Expected Outcome: FDA approval is highly likely, which is expected to be a significant value inflection point for the company.

Investment Strategy

• Investment Rating: Buy / High Risk
• Reasoning:
  • LNZ100 demonstrated significantly better durability than Vuity (up to 10 hours vs. 6 hours)
  • Improved safety profile with no major safety concerns
  • Strong management team and marketing experience
• Peak Sales Estimate (2039): ~$630M in risk-adjusted sales
• Target Price: $45, based on a DCF analysis with a WACC of 10%

Risks

• High Risk Rating: Due to typical biotech volatility and uncertainty in drug development and regulatory outcomes
• Downside Risks:
  1. Failure to achieve FDA approval
  2. Unexpected safety signals post-marketing
  3. Insufficient market education/awareness leading to underperformance relative to model expectations

Company Background

• Founded: 2013
• Headquarters: San Diego, California
• Public Listing: Reverse merger with Graphite Bio in March 2024
• Clinical Trials:
  • Ph2: INSIGHT trial showed significant near vision improvement
  • Ph3: CLARITY 1, 2, and 3 studies yielded positive and consistent results

Analyst and Disclosure Information

• Analyst: Yigal Nochomovitz, Ph.D.
• Contact: yigal.nochomovitz@citi.com | +1-212-816-1441
• Important Disclosures:
  • Citi Research may have conflicts of interest due to investment banking relationships
  • Citi Research is a liquidity provider and may trade in the securities of the issuer
  • Analysts may not be subject to FINRA Rule 2241 restrictions if not employed by Citigroup Global Markets Inc.
  • Citi has a net short position of 0.5% in LENZ common equity
  • Citi has received compensation from LENZ for investment banking services

Summary of Analyst Actions

• Previous Target Prices:
  • April 10, 2024: $34.00
  • August 21, 2024: $32.00
  • November 7, 2024: $44.00
  • March 19, 2025: $47.00
• Current Target Price: $45.00
• Current Price (June 9, 2025): $31.96

Investment Rating Definitions

• Buy: Expected total return (ETR) of 15% or more (or 25% for High Risk)
• Neutral: No clear ETR
• Sell: Negative ETR
• High Risk: Reflects both price volatility and fundamental uncertainties

Additional Notes

• Catalyst Watch/STV Disclosure:
  • Catalyst Watch is for high confidence events (e.g., FDA approval)
  • STV is for moderate confidence
  • These do not affect the fundamental investment rating
• FINRA Disclosure:
  • Catalyst Watch Upside corresponds to a Buy recommendation
  • Catalyst Watch Downside corresponds to a Sell recommendation
  • No View corresponds to Hold
• Legal and Regulatory Compliance:
  • Citi Research has policies to manage conflicts of interest
  • The communication is not intended for retail clients in Israel
  • U.S. persons may be prohibited from investing in certain companies under Executive Order 13959